CDMO
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Private Equity Deal
Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, biologics CDMO, private equity acquisition, $1.1 billion deal
Nucleus RadioPharma Unveils Ambitious Expansion Plan to Triple Production Capacity and Create 100 New Positions
Nucleus RadioPharma, Radiopharma CDMO, Manufacturing Expansion, Job Creation, Radiopharmaceuticals, Radiotherapeutics
Samsung Biologics Secures $1.2 Billion Production Contract, Boosting 2024 Deal Value to Over $3.3 Billion
Samsung Biologics, CDMO, Contract Manufacturing, Biopharmaceuticals, Production Contract, 2024 Deal Value
Catalent Sells New Jersey Facility and HQ to Ardena, Expanding Belgian CDMO’s US Footprint
Catalent, Ardena, New Jersey manufacturing plant, HQ sale, CDMO expansion, pharmaceutical manufacturing
Zealand’s Hypoglycemia Drug Faces Second FDA Rejection Due to Manufacturing Issues
Zealand Pharma, FDA rejection, dasiglucagon, congenital hyperinsulinism, hypoglycemia, CDMO inspection
CDMO Serán Secures $200M Investment from Bain Capital to Establish First Commercial Facility
CDMO Serán, Bain Capital, commercial facility, biopharmaceutical manufacturing, investment
FDA Issues Warning Letter to Indian CDMO Brassica for Data Falsification and Poor Hygiene Practices
FDA, Warning Letter, Brassica Pharma, Data Falsification, Poor Hygiene, Indian CDMO, CGMP Violations
Agilent Technologies Acquires Biovectra for $925 Million to Enhance Biologics and CRISPR Capabilities
Agilent Technologies, Biovectra, Acquisition, Biologics, CRISPR, Contract Development and Manufacturing Organization (CDMO)
Rovi Receives Acquisition Offers for CDMO Unit Worth €2B to €3B
Rovi, CDMO, Acquisition Offers, Private Equity, Biogen, Deal Making
GenScript ProBio Launches New Gene Therapy Production Plant in New Jersey
GenScript ProBio, Gene Therapy, Production Plant, New Jersey, CDMO, Biotech